PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine

The Journal of Headache and Pain

Research

Messoud Ashina¹  Sarah Louise Christensen²  Jes Olesen²  Charlotte Ernstsen²  Song Guo³  Anders Hay-Schmidt⁴  David Møbjerg Kristensen⁵ 

[1] Department of Neurology, Danish Headache Center, Human Migraine Research Unit, Copenhagen University Hospital Rigshospitalet-Glostrup, Copenhagen, Denmark;Department of Neurology, Danish Headache Center, Research Institute, Copenhagen University Hospital-Rigshospitalet Glostrup, Nordstjernevej 42, 2600, Copenhagen, Glostrup, Denmark;Department of Neurology, Danish Headache Center, Research Institute, Copenhagen University Hospital-Rigshospitalet Glostrup, Nordstjernevej 42, 2600, Copenhagen, Glostrup, Denmark;Department of Odontology, Faculty of Health, Panum Institute, University of Copenhagen, Copenhagen, Denmark;Department of Odontology, Faculty of Health, Panum Institute, University of Copenhagen, Copenhagen, Denmark;Department of Science and Environment, Roskilde University, Universitetsvej 1, Rosklide, Denmark;Univ Rennes, INSERM, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France;

关键词: PACAP;    Levcromakalim;    GTN;    Migraine;    Von Frey;    Monoclonal antibodies;   

DOI  :  10.1186/s10194-022-01523-8

 received in 2022-08-02, accepted in 2022-11-04,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundCalcitonin gene-related peptide (CGRP) antagonizing drugs represents the most important advance in migraine therapy for decades. However, these new drugs are only effective in 50–60% of patients. Recent studies have shown that the pituitary adenylate cyclase-activating peptide (PACAP38) pathway is independent from the CGRP signaling pathway. Here, we investigate PACAP38 signaling pathways in relation to glyceryl trinitrate (GTN), levcromakalim and sumatriptan.MethodsIn vivo mouse models of PACAP38-, GTN-, and levcromakalim-induced migraine were applied using tactile sensitivity to von Frey filaments as measuring readout. Signaling pathways involved in the three models were dissected using PACAP-inhibiting antibodies (mAbs) and sumatriptan.ResultsWe showed that PACAP mAbs block PACAP38 induced hypersensitivity, but not via signaling pathways involved in GTN and levcromakalim. Also, sumatriptan has no effect on PACAP38-induced hypersensitivity relevant to migraine. This is the first study testing the effect of a PACAP-inhibiting drug on GTN- and levcromakalim-induced hypersensitivity.ConclusionsBased on the findings in our mouse model of migraine using migraine-inducing compounds and anti-migraine drugs, we suggest that PACAP acts via a distinct pathway. Using PACAP38 antagonism may be a novel therapeutic target of interest in a subgroup of migraine patients who do not respond to existing therapies.

【 授权许可】

CC BY   
© The Author(s) 2022. corrected publication 2023

【 图 表 】

Fig. 1

13690_2023_1130_Article_IEq45.gif

13690_2023_1130_Article_IEq33.gif

13690_2023_1130_Article_IEq19.gif

13690_2023_1130_Article_IEq13.gif